Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,427.34
(
-0.99%
)
US TECH 100
28,429.60
(
-1.26%
)
Dow Jones
49,657.43
(
-0.81%
)
Brent Oil
106.34
(
2.07%
)
Bitcoin
79,282.09
(
-2.19%
)
News Focus
News Focus
Post# of 257575
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122986
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 75491

Saturday, 04/04/2009 3:44:51 PM

Saturday, April 04, 2009 3:44:51 PM

Post# of 257575

Clevudine's different MoA makes it a good candidate for combo therapy, should it be adopted in HBV.

I think VRUS’ claim that Clevudine has “a different MoA” from other HBV nukes is partly spin. The more relevant impetus for combination therapy including Clevudine, IMO, is the comment in the bottom paragraph of #msg-36811361.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today